Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Yimin Wang, Chuling Li, Zimu Wang, Zhaofeng Wang, Ranpu Wu, Ying Wu, Yong Song, Hongbing Liu
Summary: This systematic review evaluated the efficacy and safety of immunotherapy in early and late lung cancer, finding that immunotherapy has better efficacy in early lung cancer compared to advanced lung cancer, especially when combined with chemotherapy. In terms of safety, immunotherapy, either alone or in combination with other therapies, was found to be safer in early lung cancer than in advanced lung cancer.
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.
Review
Oncology
Alisa N. Blumenthaler, Mara B. Antonoff
Summary: Around half of NSCLC patients have metastatic disease at diagnosis, some with limited metastatic sites termed oligometastasis. Aggressive treatment of oligometastasis has shown improved survival rates, but the lack of a universal definition hinders comparison between studies.
Review
Oncology
Daijiro Harada, Nagio Takigawa
Summary: Retrospective studies support the effectiveness of the strategy of OPD and LAT in treating NSCLC patients with driver mutations, and it is expected to have some effect in patients without driver mutations in certain conditions. After combination therapy of immune checkpoint inhibitors and chemotherapy, LAT with radiotherapy may also have a positive impact.
Review
Immunology
Miguel Garcia-Pardo, Teresa Gorria, Ines Malenica, Stephanie Corgnac, Cristina Teixido, Laura Mezquita
Summary: Immunotherapy has revolutionized the oncology field and become a new standard of care for NSCLC. However, not all patients benefit from immunotherapy, and there is a need for further strategies to improve outcomes. Therapeutic cancer vaccines have the potential to boost antitumor immunity and work synergistically with immune checkpoint inhibitors. However, current vaccine immunization strategies for lung cancer have been unsuccessful. The success of COVID-19 vaccines raises hope that a similar strategy can be successful in cancer treatment.
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Katie Jasper, Brendon Stiles, Fiona McDonald, David A. Palma
Summary: This review summarizes the benefits of local ablative therapies in patients with oligometastatic disease in non-small-cell lung cancer and discusses a modern framework for treatment management.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.